Patent Number: 6,255,281

Title: Use of recombinant human uteroglobin in treatment of inflammatory and fibrotic conditions

Abstract: Method for treatment of inflammatory and fibrotic conditions in vivo using pure rhUG is disclosed. Method for treating or preventing inflammatory or fibrotic conditions characterized by a deficiency of endogenous functional UG is also disclosed. Compositions containing pure rhUG, optionally also containing lung surfactant, and assay procedures for detection of UG-fibronectin complexes, are also provided.

Inventors: Pilon; Aprile L. (Gaithersburg, MD), Mukherjee; Anil B. (Brookeville, MD), Zhang; Zhongjian (Rockville, MD)

Assignee: Claragen, Inc. and U.S. Government

International Classification: A61Q 19/00 (20060101); A61K 8/30 (20060101); A61K 38/17 (20060101); A61K 8/64 (20060101); A61K 8/96 (20060101); A61K 8/98 (20060101); C07K 14/435 (20060101); A61Q 17/00 (20060101); C12N 15/85 (20060101); C07K 14/47 (20060101); A61K 38/00 (20060101); A61K 038/17 (); C07K 014/435 ()

Expiration Date: 07/03/2018